The ethiology of DCM is very heterogeneous (1). About one third of the cases are familial. Even then, the genetic background is diverse and several genes have been reported to associate with DCM. Disappointingly, many of the genes or mutations have been found only in single or few individuals and do not explain the disease at the population level. Lamin A/C gene, which codes for lamin A and C of the nuclear inner membrane by alternative splicing, is an exception to this rule. Within a decade, LMNA has turned out to be clinically the most important gene causing DCM (2-4). In earlier studies, the autosomal dominant cardiomyopathy caused by LMNA has typically been characterized by atrioventricular block, serious heart failure, atrial fibrillation, ventricular tachycardias and ventricular fibrillation and sudden death, often appearing by middle-age. Apart from DCM, defects of the LMNA gene may cause an astonishing variety of diseases ranging from neuromuscular diseases like Emery-Dreifuss muscular dystrophy type 2, cardiac and skeletal muscle disease to rare entities like extremely early aging in Hutchinson’s progeria (5).
It has been shown that the prognosis of patients with LMNA cardiomyopathy is worse than that of DCM patients without LMNA mutations (6). The prevalence of LMNA mutations among subjects who had undergone heart transplantation has been up to 9% (7).
The study reported by Pasotti et al is so far the largest cardiologic follow-up of LMNA gene carriers. The median follow -up time was 57 months (interquartile range 36 to 107 months), allowing evalution of genetic and some nongenetic factors affecting the prognosis of these subjects. Although the study was a retrospective one, the results confirm the earlier observations demonstrating that LMNA mutations causing cardiomyopathy are highly penetrant and the disease is malignant (8). As a new finding, it was reported that previous competitive sports, lasting for at least ten years, predicted adverse cardiac events.
In clinical practice, the risk stratification of individual DCM patients is often difficult. Based on the study of Pasotti et al. and other previous reports, even taking into account the fact that several different mutations have been described and the phenotype genotype-relationships are not always well known, it seems that in general cardiomyopathy caused by LMNA mutations is a serious disease with a high risk of sudden cardiac death. Identifying mutation carriers by genetic testing might affect the prognosis. The availability of genetic testing is increasing and several laboratories are capable of sequencing major disease genes causing DCM, LMNA included. Although the prices are still quite high, genetic testing for LMNA gene defects at least in DCM subjects with atrioventricular block and/or neuromuscular findings is well argumented (9). The family members of DCM patients, who could have inherited the same defect, should also be examined, either by genetic testing and /or clinically (ECG and Echo). Subjects carrying a LMNA mutation should be carefully followed up, bearing in mind the possible need of bivent/ICD therapy or even timely heart transplant. Those considering competitive sports could be informed about the possible adverse cardiac effects of competitive sports later in life.
It has been shown that the prognosis of patients with LMNA cardiomyopathy is worse than that of DCM patients without LMNA mutations (6). The prevalence of LMNA mutations among subjects who had undergone heart transplantation has been up to 9% (7).
The study reported by Pasotti et al is so far the largest cardiologic follow-up of LMNA gene carriers. The median follow -up time was 57 months (interquartile range 36 to 107 months), allowing evalution of genetic and some nongenetic factors affecting the prognosis of these subjects. Although the study was a retrospective one, the results confirm the earlier observations demonstrating that LMNA mutations causing cardiomyopathy are highly penetrant and the disease is malignant (8). As a new finding, it was reported that previous competitive sports, lasting for at least ten years, predicted adverse cardiac events.
Conclusion:
Clinical implicationsIn clinical practice, the risk stratification of individual DCM patients is often difficult. Based on the study of Pasotti et al. and other previous reports, even taking into account the fact that several different mutations have been described and the phenotype genotype-relationships are not always well known, it seems that in general cardiomyopathy caused by LMNA mutations is a serious disease with a high risk of sudden cardiac death. Identifying mutation carriers by genetic testing might affect the prognosis. The availability of genetic testing is increasing and several laboratories are capable of sequencing major disease genes causing DCM, LMNA included. Although the prices are still quite high, genetic testing for LMNA gene defects at least in DCM subjects with atrioventricular block and/or neuromuscular findings is well argumented (9). The family members of DCM patients, who could have inherited the same defect, should also be examined, either by genetic testing and /or clinically (ECG and Echo). Subjects carrying a LMNA mutation should be carefully followed up, bearing in mind the possible need of bivent/ICD therapy or even timely heart transplant. Those considering competitive sports could be informed about the possible adverse cardiac effects of competitive sports later in life.
Our mission: To reduce the burden of cardiovascular disease.